Ablation by three-dimensional electroanatomical mapping versus anti-arrhythmic drug therapy: a cost-utility analysis in the treatment of idiopathic ventricular arrhythmias

Table 3 Mean cost-utility ratio and incremental cost-utility ratio for each intervention group in patients with idiopathic ventricular arrhythmias from the National cardiovascular Institute INCOR EsSalud

Cost Utility variable	Temporal horizon 4 years		Temporal horizon Life expectancy
Cost Utility variable	3D ablation N = 34	Antiarrhythmic N = 18	3D ablation N = 34	Antiarrhythmic N = 18
Total average cost (USD)	7,234.81	2,136.51	7,910.12	9,581.34
Utility¹	0.85	0.68	0.85	0.68
QALY²	112.42	53.69	1164.58	266.97
Average QALY	3.30	2.98	34.25	14.83
ACUQ³	2,187.26	716.31	230.94	646.01
IUCR⁴	15,684.78		-86.05

¹Utility was obtained from the average total standardized score obtained from the application of the SF-36v2 questionnaire divided by 100
²QALY = Quality-adjusted life years
³ACUR = Average Cost-Utility Ratio (Average total cost/average QALY)
⁴IUCR = Incremental Utility Cost Ratio (difference in total average costs/difference in average QALY)

ISSN: 1471-2261